Grants for For profit organizations other than small businesses - Science and Technology

This grant provides financial support to local nonprofits and organizing committees in Mankato to create or sustain community events that benefit the local economy and are open to the public.

The Regional Alliances and Multistakeholder Partnerships to Stimulate (RAMPS) Cybersecurity Education and Workforce Development (RAMPS) Program seeks to build multistakeholder workforce partnerships of employers, schools and institutions of higher education, and other community organizations. Effective multistakeholder workforce partnerships will organize multiple employers with skill shortages in specific occupations to focus on developing the skilled workforce to meet industry needs within the local or regional economy.

This funding opportunity supports researchers and organizations developing innovative tissue grafts to restore damaged brain tissue, targeting chronic neurological conditions affecting millions of people.

The FY24 RCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. The Concept Award is not intended to support an incremental progression of an already established research project; instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not required. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of rare cancers or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i., Full Application Submission Type, for more information.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 RCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs, and other federal government agencies are highly encouraged.DOD FY24 Rare Cancers Concept Award 5These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

This program provides funding to establish community-based telehealth resources that connect rural veterans with healthcare providers, improving their access to essential medical services.

This program provides funding to local governments, nonprofits, and redevelopment authorities in Pennsylvania to revitalize downtown areas and enhance community development through various improvement projects.

The FY24 PCRP Implementation Science Award supports studies that are expected to bridge the gap between research, practice, and policy through establishment of a knowledge base of interventions, clinical practices/guidelines, tools, and policies that can be deployed to targeted populations at the appropriate time and point of need. For the purposes of this funding opportunity, an implementation science study accesses strategies used and develops tools to enhance the systematic uptake of evidence-based health interventions into clinical and/or community settings in order to improve patient outreach, patient outcomes, and/or the effectiveness of health care.Impact: Research supported by the Implementation Science Award is expected to have the potential for major, near-term impact that will accelerate the widespread adoption of evidence-based practices in prostate cancer care, prevention, and survivorship. Applications are expected to identify the prostate cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Applications must also include a detailed research transition plan that articulates the pathway to moving the projects findings to the next phase for widespread clinical impact after successful completion of the award. Research transition plans are encouraged to consider future strategies targeting the patient, physician/provider, community, and/or healthcare system levels as applicable.Community Engagement: Applications are required to include members of the targeted population and/or community in the development and execution of the research project where appropriate. The research team must include one or more prostate cancer consumer advocate(s) or member(s) of the community, who will be integral throughout the planning and performance of the research project. Consumer advocates and/or community-based members should be involved in the development of the research question, project design, oversight, recruitment, and evaluation and dissemination of outcomes, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings; communication between the research team and the community should be frequent and bidirectional. The consumer advocates can be individuals who have been diagnosed with prostate cancer, a direct caregiver for someone who has been diagnosed with prostate cancer, or other representatives from the targeted community who are positioned to effect change. The consumer advocates and/or community-based members should have a high level of knowledge of current prostate cancer issues and the appropriate background in prostate cancer research and/or clinical care to contribute to the project or be otherwise positioned within the target community to effect changes in behavior based on projected outcomes. A list of implementation science resources and community or advocacy organizations is provided at the end of the Implementation Science Award Information section.Health Equity and Disproportionately Affected Populations: Regardless of the FY24 PCRP Overarching Challenge(s) being addressed, all research projects are strongly encouraged to consider health equity (e.g., access to evidence-based care) and/or have a focus on addressing the needs of disproportionately affected populations in the application.Research Scope: The Implementation Science Award mechanism is intended to fund studies including, but not limited to, the following: Small-scale clinical trials (up to phase 2) that contain clear reporting and implementation strategies to narrow the research-to-practice timeline and improve care for prostate cancer survivors, particularly within disproportionately affected populations Interventions that focus on behavioral or lifestyle changes at the patient, provider, community, and/or policy level Comparative effectiveness research establishing the benefits and harms of emerging or standard-of-care interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings Development and evaluation of strategies to overcome barriers to health care access across the cancer care continuum Altering the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines.Preliminary data to support the scientific rationale and feasibility of the research approaches are required. These preliminary data do not need to have been generated solely in prostate cancer. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.Investigators proposing a clinical trial are highly encouraged to consider leveraging the PCRP Prostate Cancer Clinical Trials Consortium (https://pcctc.org) to facilitate the rapid initiation and completion of the trial.Correlative studies that are associated with ongoing clinical trials, and preclinical studies involving the use of animals do not meet the intent of the FY24 PCRP Implementation Science Award.Partnering Principal Investigator (PI) Option: The FY24 PCRP Implementation Science Award encourages applications that include meaningful and productive collaborations between two investigators. The PIs may have expertise in similar or disparate scientific and/or clinical disciplines, but each PI is expected to bring distinct contributions to the application. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.A Clinical Trial Option allows for studies proposing small-scale clinical trials with a focus on implementation science. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Applications proposing a clinical trial are expected to provide detailed plans for initiating the clinical study within the first year, including U.S. Food and Drug Administration (FDA) Investigational New Drug/Investigational Device Exemption application submission plans, within 60 days of the award.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Implementation Sciences Resources: Potential applicants for this award are encouraged to seek collaborations and access to appropriate study populations through the following (or similar) resources: CDMRP: Search the CDMRP awards database at https://cdmrp.health.mil. The North Carolina Louisiana Prostate Cancer Project (PCaP): The PCaP was supported by the PCRP to conduct prostate cancer health disparity studies and developed a large biorepository of health disparity-related epidemiological data and biospecimens that may be requested for use by the research community. Information on PCaP investigators, data, and specimens is available at https://pcap.bioinf.unc.edu. National Cancer Institute Center to Reduce Cancer Health Disparities: Search for health disparity research and researchers at https://crchd.cancer.gov/index.html. National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Community-Based Participatory Research (CBPR) Initiative: Contact the NIMHD at https://www.nimhd.nih.gov/programs/extramural/community-based-participatory.html for information on current CBPR programs and scientists and communities engaged in health disparity research. Cancer Prevention and Control Research Network (CPCRN): Contact the CPCRN at https://cpcrn.org/ for information on community participatory research to reduce cancer in disproportionately affected populations. Health Resources and Services Administration, Office of Minority Health: Search for health disparity programs and funded investigators at https://www.hrsa.gov/index.html. NIH Research Portfolio Online Reporting Tool (NIH RePORTER): Search for NIH awards at https://projectreporter.nih.gov/reporter.cfm. Defense Technical Information Center (DTIC): Search for Department of Defense (DOD) and other government-funded investigators through DTIC Technical Reports at https://discover.dtic.mil/. National Library of Medicine, NIH, PubMed: Search for investigators publishing studies on prostate cancer health disparities at https://www.ncbi.nlm.nih.gov/pubmed. U.S. Department of Education: Search for institutions that may have increased access to disproportionately affected populations at https://www2.ed.gov/about/offices/list/ocr/edlite-minorityinst.html. International Cancer Research Partnership: Search for investigators and studies relevant to health disparity that are supported by cancer research funders from several countries including the United States, European Union, United Kingdom, and Canada at https://www.icrpartnership.org. National Coalition for LGBT Health: For more information on programs focused on Lesbian, Gay, Bisexual, and Transgender (LGBT) research, policy, education, and training, search https://www.healthlgbt.org. National LGBT Cancer Network: To obtain more information, search https://www.cancer-network.org.In addition, the following is a list of potential community and/or advocacy organizations that applicants may find helpful to satisfy the requirement for community engagement within their proposed studies: the American Indian Health Care Association, National African American Outreach Program of the Patient Advocate Foundation, National Alliance for Hispanic Health, National Medical Association, National Rural Health Association, and Prostate Health Education Network, as well as international organizations such as the African-Caribbean Cancer Consortium, African Organization for Research and Training in Cancer, Europa Uomo, European Cancer Patient Coalition, Global Prostate Cancer Alliance, Malecare, Men of African Descent and Carcinoma of the Prostate Consortium, Prostate Cancer Transatlantic Consortium, Urban League, and The Prostate Net.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Implementation Science Award should not exceed $2.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $9.6M to fund approximately three PCRP Implementation Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Distributed Array of Small Instruments (DASI) solicitation is designed to address the increasing need for high spatial and temporal resolution measurements to determine the local, regional, and global scale processes that are essential for addressing the fundamental questions insolar and space physics. This solicitation will be formally divided into two tracks: 1) development of instrumentation for future deployment in arrays and 2) deployment and operation of existing instruments in distributed arrays.This DASI solicitation emphasizes both strong scientific merit and a well-developed plan for student training and involvement of a diverse workforce.

The "Level Up LB: Extreme Small Business Makeover and Grant Program," launched by the City of Long Beach, is an initiative designed to enhance the success and sustainability of small businesses. While the description doesn't explicitly detail a "foundation mission alignment," the program itself aligns with the broader civic mission of economic development and community prosperity. By empowering local entrepreneurs, the City of Long Beach aims to strengthen its local economy and foster a vibrant business environment, thereby contributing to the overall well-being of its residents and community. The program targets small businesses located and operating within Long Beach, California, with a storefront accessible to the public. Eligible businesses must have been in operation for a minimum of three years as of April 23, 2024, be independently-owned for-profit entities (including sole proprietorships, LLCs, or Corporations that are not publicly traded), or 501(c)3 nonprofits. They must hold an active or delinquent City of Long Beach business license, be currently open and active, and earn no more than $5 million in annual gross revenue. Corporations, LLCs, and limited partnerships must have an "ACTIVE" status with the California Secretary of State. The program excludes businesses without a physical location, permanently closed businesses, government entities, political/lobbying activities, passive businesses, religious organizations, financial lending businesses, landlords/property managers (unless repairing on behalf of a small business), illegal activities, socially undesirable activities (e.g., check cashing), businesses with active code enforcement/COVID-19 Health Order violations, and cannabis-related businesses. The program's priorities and focuses include igniting growth and fostering excellence among Long Beach's small businesses. Through no-cost training sessions, participants will receive comprehensive support in strategic business planning, marketing, branding, social media optimization, access to capital, government procurement, permitting/licensing, merchandising, networking, biz-to-biz mentorship, talent recruitment, and personalized business counseling. A selection committee will determine program participants and grant awards based on representation across all parts of the city (with priority for low-to-moderate income areas), representation across multiple sectors, and business readiness and potential impact of program participation. Expected outcomes and measurable results include participants becoming eligible to apply for $10,000 grants upon completion of the program, which are intended to empower them to expand their business capacity and enhance resilience. The City’s Economic Development Department will select a group of 25 small businesses for this exclusive opportunity. The focus on comprehensive workshops and subsequent grant eligibility directly aims to translate the acquired knowledge and resources into tangible business expansion and increased sustainability. While specific quantitative metrics for growth and resilience are not detailed, the program's structure implies that the successful utilization of the grants and learned strategies will be key indicators of impact.

This funding opportunity provides financial support to local businesses and non-profits for community-focused projects that promote public engagement, enhance public spaces, and foster economic growth in Hyattsville.

The Placer County Air Pollution Control District's Clean Air Grant (CAG) Program is designed to provide monetary grants to private companies and public agencies. The core mission of this program aligns with the broader goal of improving air quality by incentivizing actions that reduce emissions from heavy-duty engines. This goes beyond existing legal or regulatory requirements, encouraging a proactive approach to environmental stewardship. The program's strategic priority is to accelerate California's transition towards zero and near-zero emission technologies, addressing both local air quality and broader climate change concerns. The target beneficiaries of the CAG Program are diverse and include private companies, public agencies, and specific segments within these, such as small fleets for off-road funding, and entities operating school buses. A significant portion of the funds is reserved for projects located within or directly benefitting low-income communities, indicating a strong focus on environmental justice and equitable distribution of environmental benefits. The impact goals are centered on achieving surplus emission reductions, particularly from heavy-duty on-road and off-road equipment, and supporting infrastructure for cleaner technologies. The program prioritizes several key areas. These include agricultural portable and stationary engine repower and infrastructure, alternative fuel infrastructure (such as battery charging, natural gas, and hydrogen fueling stations), heavy-duty on- and off-road equipment replacement, repower, and retrofit, and school bus replacement. There is a clear emphasis on zero-emission technology and infrastructure, which is a guiding principle for the program. The District also considers special projects for sensitive receptors, further demonstrating a commitment to protecting vulnerable populations from air pollution. Expected outcomes include a measurable reduction in air toxics, criteria air pollutants, and greenhouse gas emissions. The program aims to achieve these reductions through investments that directly benefit impacted communities. While specific measurable results are not detailed in terms of quantifiable targets (e.g., "reduce NOx by X tons"), the guiding principles suggest a commitment to considering cost-effectiveness and exposure reduction in funding decisions, implying a data-driven approach to evaluating impact. Transparency in project selections and reporting is also a stated guiding principle, which will contribute to the accountability and effectiveness of the program.

This initiative provides financial support and mentorship to minority-owned small businesses in specific West Side neighborhoods of Chicago, helping them grow and contribute to their communities.

This funding opportunity supports U.S. institutions in developing open-source science projects that improve the accessibility and reproducibility of NASA research, encouraging community engagement and collaboration.

The Illinois Department of Commerce and Economic Opportunity (DCEO) is offering two grant programs: the Rebuild Downtowns & Main Streets (RDMS) Capital Grant Program and the Research in Illinois to Spur Economic Recovery (RISE) Implementation Grant Program. Both programs aim to accelerate Illinois' economic recovery and promote long-term, sustainable, and inclusive growth, aligning with a mission to revitalize communities and foster economic development. The total funding expected is $20 million for RDMS and $10 million for RISE Implementation, with individual grants ranging from $250,000 to $2 million. The RDMS program specifically targets communities that have experienced disinvestment, particularly those hardest-hit by the COVID-19 crisis. The goal is to facilitate investment to revitalize commercial corridors and downtown areas in Illinois through capital grants. Eligible applicants for both programs include economic development organizations (EDOs), local units of government (e.g., municipalities, counties, townships), and private businesses. Special purpose local units of government are not eligible. The priorities for RDMS include supporting capital projects that improve and repair roads, sidewalks, and lighting; develop public spaces to attract events; improve water and sewer infrastructure; and facilitate mixed-use development to add vitality to commercial corridors and downtowns. These priorities are aimed at tangible infrastructure and development projects that directly contribute to the revitalization of downtown areas. Expected outcomes for these programs include accelerated economic recovery and the promotion of long-term, sustainable, and inclusive growth throughout Illinois. Measurable results will likely involve the number and scale of capital projects completed, the revitalization of commercial corridors, increased economic activity in targeted areas, and improvements in public infrastructure. The grant duration is 2 years, with the period of performance expected to be late calendar year 2024 through the end of calendar year 2026. The DCEO's strategic priority is clearly to stimulate economic recovery and growth through targeted investments in key community infrastructure and development.

This program provides matching grants to local businesses in Libertyville to support growth and sustainability through various improvements, excluding general operational costs.

The NIST-Hawaii Partnership in Plastic Pollution Research is seeking applications from eligible applicants to establish an institutional award, as described in the Department of Commerce Grants and Cooperative Agreements Manual, Chapter 6.A.2 (20 April 2021), for activities to partner on the nations priority plastic pollution research with efforts focusing on the Hawaiian Island region. Eligible applicants should describe how they can host and interact with at least three NIST scientists with office, laboratory and other appropriate facilities to perform multi-disciplinary plastic pollution research with the intent to establish a long-term partnership between NIST and the recipient, as discussed in Section I.1. The proposal should also include a description of administrative, research and outreach/educational support that would be offered by the applicant in the partnership to achieve world-class research in the field of plastic pollution.

This funding opportunity supports innovative research projects aimed at developing new therapies for Amyotrophic Lateral Sclerosis (ALS), encouraging high-risk ideas that include biomarker development to guide future clinical applications.

This funding opportunity supports research and technology development in advanced telecommunications systems for various industries, including healthcare and transportation, targeting academic institutions, nonprofits, and businesses to foster innovation and collaboration.

To implement a project aimed at advancing U.S. foreign policy and national security priorities by supporting initiatives that make decision-making structures and processes in fragile, conflict, or crisis-affected contexts more reflective of and responsive to the needs and perspectives of partner states to ensure strategic trade control systems meet international standards and by engaging on bilateral, regional and multilateral levels with foreign governments to aid in the establishment of independent capabilities to regulate transfers of weapons of mass destruction, WMD-related items, conventional arms, and related dual-use items, and to detect, interdict, investigate, and prosecute illicit transfers of such items.

The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.The following are important aspects of the EHDA: Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism. Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative: Explores a novel idea and/or research question in TSC research and/or patient care. Uses or develops novel methods or technologies to address a question in TSC research and/or patient care. Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended.